Dr. Binhui Ren 任斌辉
Chief Physician, Associate Professor
Department of Thoracic Surgery, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive treatment of lung nodules, including multiple nodules; minimally invasive and comprehensive surgical treatment of mediastinal tumors; comprehensive treatment of lung and esophageal cancer; prevention and management of perioperative complications in esophageal cancer.
Dr. Ren holds a PhD in Surgery and completed a two-year visiting study at MD Anderson Cancer Center. Research focuses on comprehensive diagnosis and treatment of lung and esophageal cancer, and molecular mechanisms of lung cancer metastasis. Dr. Ren leads eight research projects, including National Natural Science Foundation grants, and has published 18 SCI papers.
Professional roles
- Member, Lung Cancer Expert Committee, Oncology Branch, Chinese Medical Association
- Youth Member, Clinical Nutrition Committee, Surgical Physicians Branch, Chinese Medical Doctor Association
- Member, Thoracic Surgery Branch, Jiangsu Medical Association
- Member, Esophageal Cancer Professional Committee, Jiangsu Anti-Cancer Association
Name order: in Chinese the family name comes first (Ren Binhui). Papers usually list the name as Binhui Ren or Ren B.
Selected publications
32 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Oncol (Dordr), 2026 (senior author): Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis. PubMed 42455236
- J Thorac Dis, 2025 (senior author): Association of perioperative cholesterol depletion with anastomotic leak after esophagectomy for cancer: a retrospective study. PubMed 41522112
- J Biochem Mol Toxicol, 2025 (senior author): DLX6 Drives Lung Adenocarcinoma Progression via the p27(Kip1)/CDK2-CCNE1 Signaling Pathway. PubMed 41392461
- Cell Death Dis, 2025 (senior author): SKA3-mediated hypoxia tolerance and metabolic reprogramming promote liver metastasis in lung adenocarcinoma. PubMed 41298345
- Mol Cell Biochem, 2025 (senior author): SKA3 promotes lung adenocarcinoma progression via the EGFR/E2F1/SKA3/integrin β1 signaling loop. PubMed 40056339
- World J Surg Oncol, 2022 (senior author): An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma. PubMed 35354488
- Mol Ther Nucleic Acids, 2021 (senior author): lncRNA GAS6-AS1 inhibits progression and glucose metabolism reprogramming in LUAD via repressing E2F1-mediated transcription of GLUT1. PubMed 34141461
- Support Care Cancer, 2021 (senior author): Esophageal cancer patients of heavier weight have more nutritional risk of inadequate calorie intake immediately after esophagectomy: a retrospective study. PubMed 32621261
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion